Skip to main content
JAMA Network logoLink to JAMA Network
. 2021 Apr 6;325(13):1335. doi: 10.1001/jama.2021.2802

Errors in Results

PMCID: PMC8025105  PMID: 33821919

The Original Investigation titled “Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes,”1 published in the April 14, 2020, issue of JAMA, included errors in the Results section. This included labeling weight decline in those with diabetes as weight decline in those without diabetes at 8 months, citing reference 18 rather than reference 16 in footnote “b” in Table 2, and not indicating that the absolute difference in cardiovascular death or hospitalization for heart failure among patients with diabetes was presented as a percentage in Table 2. The text and table have been corrected. (All other information in the Results is correct and remains unchanged.)

Reference

  • 1.Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353-1368. doi: 10.1001/jama.2020.1906 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA are provided here courtesy of American Medical Association

RESOURCES